Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in PCED

MILAN & SAN MATEO, Calif.--(BUSINESS WIRE)--Dompé advances Phase 3 study of Cenegermin-bkbj (a rhNGF) for PCED, a rare condition with high unmet clinical need.